David Thomas, FRACP, PhD, director and division head, Genomic Cancer Medicine, Cancer Division, Garvan Institute of Medical Research, discusses the genomic features of sarcoma and how they factor into the treatment landscape of this disease.
Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer
March 28th 2023New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.
Read More
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer
March 27th 2023The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512